CSafe expands cold chain offerings for the Cell and Gene Therapy market with launch of high-performing AcuTemp Plus Series of temperature-controlled packaging

Tuesday, December 3, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

CSafe Global recently expanded its passive packaging portfolio by launching the new and innovative AcuTemp Plus Series of solutions to address the temperature-controlled shipping needs of commercial pharmaceuticals, clinical trials, and emerging cell and gene therapies.

DAYTON, Ohio, Dec. 3, 2019 /PRNewswire/ -- CSafe Global understands temperature control, gained from 40 years of experience in developing innovative temperature-controlled packaging - from solutions designed to transport vital pediatric vaccines to crucial life-saving cancer drugs. CSafe is known for protecting what matters most to pharmaceutical companies, so that patients receive what matters most to them.

CSafe recognizes the importance of thermally protecting shipments of life-enhancing medications as they are shipped to patients in need around the world. The criticality of temperature protection within the emerging Cell and Gene Therapy (CGT) space is further amplified due to the value and uniqueness of CGT products and the complicated supply chain. The new AcuTemp Plus Series has been developed with this in mind, and will confidently meet the evolving and increasingly demanding customer expectations for temperature performance, solution quality, and system robustness required of packaging solutions to protect shipments of novel cell and gene therapies.

"We are proud to expand our cold chain packaging offerings for the Cell and Gene Therapy market, and have focused and invested significantly in R&D to develop best-in-class solutions to meet the demanding product requirements for this emerging class of medication," stated Patrick Schafer, CEO of CSafe Global. "Test results of the new AcuTemp Plus Series have been very impressive with temperature performances outlasting other market available solutions by a large margin."

The AcuTemp Plus Series of packaging solutions has been designed with proprietary, high-performance ThermoCor® Vacuum Insulated Panels (VIP) to guarantee precise end-to-end control of internal payload temperatures. In addition to industry-leading performance, the innovative range has been developed with simplicity in mind, benefiting from optimized system components and solution design. The new series is available in multiple size configurations and temperature profiles, along with different integrated track and trace options to meet customer needs. Furthermore, the AcuTemp Plus Series is supported with a fully managed, end-to-end service infrastructure leveraging CSafe's industry-unique retest and reuse program - REPAQ®.

With a market-leading portfolio of both active and passive temperature-management solutions, it is CSafe's mission to bring peace of mind to every life-science customer.

CONTACT: Josh Angliss, jangliss@csafeglobal.com

Cision View original content:http://www.prnewswire.com/news-releases/csafe-expands-cold-chain-offerings-for-the-cell-and-gene-therapy-market-with-launch-of-high-performing-acutemp-plus-series-of-temperature-controlled-packaging-300968270.html

SOURCE CSafe Global



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store